Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07623200 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

Study acronym: EXCALIBUR-ET2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 175 → 178 locations Eligibility criteria expanded, about 8 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 8 words
  2. Study sites: 177 to 175v5
  3. Trial sites reduced: 180 → 177 locationsv4
  4. Recruitment opened Start date: Jul 31, 2026 to Sep 8, 2026 · Trial sites expanded: 0 → 180 locationsv3 Show 2 more changesShow less
    • Start date: Jul 31, 2026 to Sep 8, 2026
    • Trial sites expanded: 0 → 180 locations
  5. Study Status, Referencesv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Trial Details
NCT Number NCT07623200
Lead Sponsor Incyte Corporation
Conditions Essential Thrombocythemia
Enrollment 426 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov